Effect of add-on therapy with leukotriene receptor antagonists and Chungsangboha-tang in patients with asthma: a protocol for a randomized, placebo-controlled, parallel, multicenter trial

Abstract Background Asthma is a chronic disease characterized by airway inflammation and obstruction. Treatment aims to control symptoms with minimal medication, using disease-controlling and symptom-relieving drugs. Inhaled steroids and beta2 agonists are common treatments; however, their long-term...

Full description

Saved in:
Bibliographic Details
Main Authors: Sung-Woo Kang, Hae-Seong Nam, Yang-Chun Park, Jun-Yong Choi, Ki-Tae Kim, Seo-Jung Ha, Kwan-Il Kim, Hee-Jae Jung, Beom-Joon Lee
Format: Article
Language:English
Published: BMC 2025-02-01
Series:BMC Complementary Medicine and Therapies
Subjects:
Online Access:https://doi.org/10.1186/s12906-025-04799-w
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850067215094644736
author Sung-Woo Kang
Hae-Seong Nam
Yang-Chun Park
Jun-Yong Choi
Ki-Tae Kim
Seo-Jung Ha
Kwan-Il Kim
Hee-Jae Jung
Beom-Joon Lee
author_facet Sung-Woo Kang
Hae-Seong Nam
Yang-Chun Park
Jun-Yong Choi
Ki-Tae Kim
Seo-Jung Ha
Kwan-Il Kim
Hee-Jae Jung
Beom-Joon Lee
author_sort Sung-Woo Kang
collection DOAJ
description Abstract Background Asthma is a chronic disease characterized by airway inflammation and obstruction. Treatment aims to control symptoms with minimal medication, using disease-controlling and symptom-relieving drugs. Inhaled steroids and beta2 agonists are common treatments; however, their long-term use can cause side effects. Leukotriene receptor antagonists (LTRAs) are used in combination with inhaled steroids to manage asthma because of their anti-inflammatory and bronchodilatory effects. Combining LTRAs with Chungsangboha-tang (CSBHT), a Korean medicine, may enhance their efficacy. This study aimed to evaluate the potential of CSBHT as an adjunctive therapy for asthma management in a randomized, placebo-controlled, double-blind, multicenter clinical trial. Methods This randomized, placebo-controlled, double-blind, parallel-group, multicenter study aims to evaluate the efficacy and safety of CSBHT as an additional treatment for patients with asthma, particularly for those with LTRAs. Overall, 198 participants will be randomly divided into intervention and control groups, with the former receiving CSBHT thrice daily and the latter receiving a placebo. Follow-ups at weeks 0, 4, and 8 will include outcome measurements, medication dispensation, and adverse reaction monitoring. The primary outcome is the mean change in forced expiratory volume in one-second scores, with secondary outcomes including changes in peak expiratory flow, forced vital capacity, forced expiratory flow 25–75%, fractional exhaled nitric oxide, Asthma Control Test, Asthma Quality of Life Questionnaire, serum IgE, eosinophil count, C-reactive protein, rescue medication usage, and a descriptive analysis of the questionnaire on asthma symptoms in Korean medicine. Safety assessments will be conducted using laboratory tests, vital signs, and monitoring of adverse events. Economic evaluations will be conducted using either cost-minimization analysis or cost-utility analysis. Discussion This trial will evaluate the efficacy, safety, and cost-effectiveness of CSBHT as an add-on therapy to LTRAs to establish its potential as an adjuvant therapy in asthma management. Trial registration This study was registered in the Clinical Research Information Service of Korea (KCT0006005), on March 16, 2021.
format Article
id doaj-art-c7074639eab344eabb90bfa6b43a7656
institution DOAJ
issn 2662-7671
language English
publishDate 2025-02-01
publisher BMC
record_format Article
series BMC Complementary Medicine and Therapies
spelling doaj-art-c7074639eab344eabb90bfa6b43a76562025-08-20T02:48:26ZengBMCBMC Complementary Medicine and Therapies2662-76712025-02-0125111210.1186/s12906-025-04799-wEffect of add-on therapy with leukotriene receptor antagonists and Chungsangboha-tang in patients with asthma: a protocol for a randomized, placebo-controlled, parallel, multicenter trialSung-Woo Kang0Hae-Seong Nam1Yang-Chun Park2Jun-Yong Choi3Ki-Tae Kim4Seo-Jung Ha5Kwan-Il Kim6Hee-Jae Jung7Beom-Joon Lee8Department of Clinical Korean Medicine, College of Korean Medicine, Graduate School, Kyung Hee UniversityDivision of Pulmonology, Department of Internal Medicine, Inha University Hospital, Inha University School of MedicineDepartment of Internal Medicine, College of Korean Medicine, Daejeon UniversityDepartment of Internal Medicine, School of Korean Medicine, Pusan National UniversityDepartment of Korean Medicine, College of Korean Medicine, Semyung UniversityDepartment of Acupuncture and Moxibustion Medicine, College of Korean Medicine, Sangji UniversityDepartment of Clinical Korean Medicine, College of Korean Medicine, Graduate School, Kyung Hee UniversityDepartment of Clinical Korean Medicine, College of Korean Medicine, Graduate School, Kyung Hee UniversityDepartment of Clinical Korean Medicine, College of Korean Medicine, Graduate School, Kyung Hee UniversityAbstract Background Asthma is a chronic disease characterized by airway inflammation and obstruction. Treatment aims to control symptoms with minimal medication, using disease-controlling and symptom-relieving drugs. Inhaled steroids and beta2 agonists are common treatments; however, their long-term use can cause side effects. Leukotriene receptor antagonists (LTRAs) are used in combination with inhaled steroids to manage asthma because of their anti-inflammatory and bronchodilatory effects. Combining LTRAs with Chungsangboha-tang (CSBHT), a Korean medicine, may enhance their efficacy. This study aimed to evaluate the potential of CSBHT as an adjunctive therapy for asthma management in a randomized, placebo-controlled, double-blind, multicenter clinical trial. Methods This randomized, placebo-controlled, double-blind, parallel-group, multicenter study aims to evaluate the efficacy and safety of CSBHT as an additional treatment for patients with asthma, particularly for those with LTRAs. Overall, 198 participants will be randomly divided into intervention and control groups, with the former receiving CSBHT thrice daily and the latter receiving a placebo. Follow-ups at weeks 0, 4, and 8 will include outcome measurements, medication dispensation, and adverse reaction monitoring. The primary outcome is the mean change in forced expiratory volume in one-second scores, with secondary outcomes including changes in peak expiratory flow, forced vital capacity, forced expiratory flow 25–75%, fractional exhaled nitric oxide, Asthma Control Test, Asthma Quality of Life Questionnaire, serum IgE, eosinophil count, C-reactive protein, rescue medication usage, and a descriptive analysis of the questionnaire on asthma symptoms in Korean medicine. Safety assessments will be conducted using laboratory tests, vital signs, and monitoring of adverse events. Economic evaluations will be conducted using either cost-minimization analysis or cost-utility analysis. Discussion This trial will evaluate the efficacy, safety, and cost-effectiveness of CSBHT as an add-on therapy to LTRAs to establish its potential as an adjuvant therapy in asthma management. Trial registration This study was registered in the Clinical Research Information Service of Korea (KCT0006005), on March 16, 2021.https://doi.org/10.1186/s12906-025-04799-wAsthmaChungsangboha-tangHerbal medicineKorea traditional medicineLeukotriene receptor antagonists
spellingShingle Sung-Woo Kang
Hae-Seong Nam
Yang-Chun Park
Jun-Yong Choi
Ki-Tae Kim
Seo-Jung Ha
Kwan-Il Kim
Hee-Jae Jung
Beom-Joon Lee
Effect of add-on therapy with leukotriene receptor antagonists and Chungsangboha-tang in patients with asthma: a protocol for a randomized, placebo-controlled, parallel, multicenter trial
BMC Complementary Medicine and Therapies
Asthma
Chungsangboha-tang
Herbal medicine
Korea traditional medicine
Leukotriene receptor antagonists
title Effect of add-on therapy with leukotriene receptor antagonists and Chungsangboha-tang in patients with asthma: a protocol for a randomized, placebo-controlled, parallel, multicenter trial
title_full Effect of add-on therapy with leukotriene receptor antagonists and Chungsangboha-tang in patients with asthma: a protocol for a randomized, placebo-controlled, parallel, multicenter trial
title_fullStr Effect of add-on therapy with leukotriene receptor antagonists and Chungsangboha-tang in patients with asthma: a protocol for a randomized, placebo-controlled, parallel, multicenter trial
title_full_unstemmed Effect of add-on therapy with leukotriene receptor antagonists and Chungsangboha-tang in patients with asthma: a protocol for a randomized, placebo-controlled, parallel, multicenter trial
title_short Effect of add-on therapy with leukotriene receptor antagonists and Chungsangboha-tang in patients with asthma: a protocol for a randomized, placebo-controlled, parallel, multicenter trial
title_sort effect of add on therapy with leukotriene receptor antagonists and chungsangboha tang in patients with asthma a protocol for a randomized placebo controlled parallel multicenter trial
topic Asthma
Chungsangboha-tang
Herbal medicine
Korea traditional medicine
Leukotriene receptor antagonists
url https://doi.org/10.1186/s12906-025-04799-w
work_keys_str_mv AT sungwookang effectofaddontherapywithleukotrienereceptorantagonistsandchungsangbohatanginpatientswithasthmaaprotocolforarandomizedplacebocontrolledparallelmulticentertrial
AT haeseongnam effectofaddontherapywithleukotrienereceptorantagonistsandchungsangbohatanginpatientswithasthmaaprotocolforarandomizedplacebocontrolledparallelmulticentertrial
AT yangchunpark effectofaddontherapywithleukotrienereceptorantagonistsandchungsangbohatanginpatientswithasthmaaprotocolforarandomizedplacebocontrolledparallelmulticentertrial
AT junyongchoi effectofaddontherapywithleukotrienereceptorantagonistsandchungsangbohatanginpatientswithasthmaaprotocolforarandomizedplacebocontrolledparallelmulticentertrial
AT kitaekim effectofaddontherapywithleukotrienereceptorantagonistsandchungsangbohatanginpatientswithasthmaaprotocolforarandomizedplacebocontrolledparallelmulticentertrial
AT seojungha effectofaddontherapywithleukotrienereceptorantagonistsandchungsangbohatanginpatientswithasthmaaprotocolforarandomizedplacebocontrolledparallelmulticentertrial
AT kwanilkim effectofaddontherapywithleukotrienereceptorantagonistsandchungsangbohatanginpatientswithasthmaaprotocolforarandomizedplacebocontrolledparallelmulticentertrial
AT heejaejung effectofaddontherapywithleukotrienereceptorantagonistsandchungsangbohatanginpatientswithasthmaaprotocolforarandomizedplacebocontrolledparallelmulticentertrial
AT beomjoonlee effectofaddontherapywithleukotrienereceptorantagonistsandchungsangbohatanginpatientswithasthmaaprotocolforarandomizedplacebocontrolledparallelmulticentertrial